Posted by Michael Wonder on 04 May 2020
Banner Life Sciences announces final FDA approval of Bafiertam for multiple sclerosis
30 April 2020 - Bafiertam (monomethyl fumarate), the bioequivalent alternative to Biogen’s Tecfidera (dimethyl fumarate), is a new oral treatment option for relapsing forms of multiple sclerosis.
Banner Life Sciences announced today that the U.S. FDA granted final approval of Bafiertam (monomethyl fumarate) delayed- release capsules for the treatment of relapsing forms of multiple sclerosis.
The FDA granted tentative approval of Bafiertam on November 16, 2018 under a new drug application submitted under the 505(b)(2) filing pathway.
